Klin Farmakol Farm. 2010;24(3):152-154
Aprepitant
- Masarykův onkologický ústav, Ústavní lékárna, Brno
An antagonist of neurokinine NK1 receptors, aprepitant is indicated for the prevention of acute and delayed nausea and vomiting in
adults related to moderate or high emetic risk anti-cancer chemotherapy. Chemotherapy induces nausea and vomiting by the means of
peripheral mechanisms that start in the course of day 1 and in which 5-HT3 receptors play the major role, as well as by the means of central
mechanisms that are triggered in the course of following days and in which neurokinine receptors are crucial. In clinical studies, the
combination of aprepitant, a corticosteroid, and a 5-HT3 antagonist proved to lead to better overall response than the mere combination
of a corticosteroid and a 5-HT3 antagonist. Adverse effects of aprepitant are similar to other antiemetics used in this indication.
Keywords: aprepitant, neurokinine receptor, antiemesis, chemotherapy
Published: October 15, 2010 Show citation
References
- Souhrn údajů o přípravku EMEND. Aktualizace z 12. 1. 2010.
- Berger AM, Clark-Snow RA. In: DeVita VT jr., et al. Cancer: Principles and Practice of Oncology (7th ed). Lippincott Williams and Wilkins. 2005: 2515-2523.
- Hesketh PJ, et al. Eur J Cancer. 2003; 39(8): 1074-1080.
- National Comprehensive Cancer Network: Practice Guidelines in Oncology, version 3. 2009: Antiemesis.
- Kris MG, Hesketh PJ, Somerfield MR, Feyer P, Clark-Snow R, Koeller JM, Morrow GR, Chinnery LW, Chesney MJ, Gralla RJ, Grunberg SM. American Society of Clinical Oncology (ASCO) Guideline for Antiemetics in Oncology: Update 2006. JCO, Vol 24, No 18.
Go to original source... 
Go to PubMed... - Herrstedt J, Roila F. Chemotherapy-induced nausea and vomiting: European Society for Medical Oncology (ESMO) Clinical Recommendations for prophylaxis. Ann Oncol 19, 2008; (Suppl 2): ii110-ii112. Go to original source... Go to PubMed...
- Schmoll HJ, Aapro MS, Poli-Bigelli S, Kim H-K, Park K, Jordan K, von Pawel J, Giezek H, Ahmed T, Chan CY. Comparison of an aprepitant regimen with a multiple-day ondansetron regimen, both with dexamethasone, for antiemetic efficacy in high-dose cisplatin treatment. Annals of Oncology. doi: 10.1093/annonc/mdl019.
- Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ. The Oral Neurokinin-1 Antagonist Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Multinational, Randomized, Double-Blind, Placebo-Controlled Trial in Patients Receiving High-Dose Cisplatin-The Aprepitant Protocol 052 Study Group. Journal of Clinical Oncology, Vol 21, No 22 (Nov 15), 2003 DOI: 10.1200/JCO.2003.01.095. Go to original source... Go to PubMed...
- Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, de Wit R, Carides AD, Taylor A, Evans JK, Horgan KJ. The oral NK1 antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: Pooled data from 2 randomised, double-blind, placebo controlled trials. European Journal of Cancer. 2005; 41: 1278-1285. Go to original source... Go to PubMed...
- Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Ma GJ, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F. Addition of the Neurokinin 1 Receptor Antagonist Aprepitant to Standard Antiemetic Therapy Improves Control of Chemotherapy-Induced Nausea and Vomiting. Cancer. 2003; 97(12): 3090-3098. Go to original source... Go to PubMed...
- Warr DG, Hesketh PJ, Gralla RJ, Muss HB, Herrstedt J, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Bohidar N, Klinger G, Hustad CM, Horgan KJ, Skobierandan F. Efficacy and Tolerability of Aprepitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer After Moderately Emetogenic Chemotherapy. JCO. 2005; 23: 12. Go to original source... Go to PubMed...
- Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T, Schmoll H-J. Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. Support Care Cancer. DOI 10.1007/s00520-009-0680-9.
- Blum RA, Majumdar A, McCrea J, Busillo J, Orlowski LH, Panebianco D, Hesney M, Petty KJ, Goldberg MR, Gail Murphy M, Gottesdiener KM, Hustad CM, Lates C, Kraft WK, Van Buren S, Waldman SA, Greenberg HE. Effects of Aprepitant on the Pharmacokinetics ofOndansetron and Granisetron in Healthy Subjects. Clinical Therapeutics, 2003; 25(5): 1407-1419. Go to original source... Go to PubMed...
- Shah AK, Hunt TL, Gallagher SC, Cullen MT. Jr. Pharmacokinetics of palonosetron in combination with aprepitant in healthy volunteers. Current Medical Research & Opinion. 2005; 21(4): 595-601. Go to original source... Go to PubMed...
- Multinational Association of Supportive Care in Cancer - Antiemetic Guidelines (Update March 2008).
- Oncology Nursing Society: Chemotherapy-Induced Nausea and Vomiting. Recommended for Practice. Information leaflet. ONS 2006.
- Howell JE, Szabatura AH, Hatfield Seung A, Nesbit SA. Characterization of the occurence of ifosfamide-induced neurotoxicity with concomitant aprepitant. J Oncol Pharm Pract 2008; 14(3): 157-162. Go to original source... Go to PubMed...